{
    "ticker": "CHEB.U",
    "name": "Chembio Diagnostics, Inc.",
    "description": "Chembio Diagnostics, Inc. is a leading point-of-care diagnostics company specializing in the development and commercialization of rapid diagnostic tests. Founded in 1985 and headquartered in Hauppauge, New York, Chembio focuses on providing innovative solutions for infectious diseases, particularly in areas where traditional laboratory testing may not be readily available. The company's product portfolio includes a range of tests for diseases such as HIV, syphilis, and COVID-19, designed to deliver results quickly and accurately. Chembio's proprietary DPP\u00ae (Dual Path Platform) technology enables the development of tests that can be performed at the patient's bedside or in remote settings, making it a valuable resource in global health initiatives. Chembio is committed to improving patient care through its innovative diagnostic solutions and has established partnerships with various organizations to enhance access to critical testing in underserved communities. The company continues to invest in research and development to expand its product offerings and meet the evolving needs of the healthcare sector.",
    "industry": [
        "Medical Devices",
        "Diagnostics"
    ],
    "headquarters": "Hauppauge, New York, USA",
    "founded": "1985",
    "website": "https://www.chembio.com",
    "ceo": "Richard Eberly",
    "social_media": {
        "twitter": "https://twitter.com/ChembioDx",
        "linkedin": "https://www.linkedin.com/company/chembio-diagnostics"
    },
    "investor_relations": "https://investors.chembio.com",
    "key_executives": [
        {
            "name": "Richard Eberly",
            "position": "CEO"
        },
        {
            "name": "John G. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Infectious Disease Tests",
            "products": [
                "DPP\u00ae HIV 1/2 Test",
                "DPP\u00ae Syphilis Test",
                "DPP\u00ae COVID-19 Test"
            ]
        }
    ],
    "seo": {
        "meta_title": "Chembio Diagnostics, Inc. | Rapid Diagnostic Tests for Infectious Diseases",
        "meta_description": "Explore Chembio Diagnostics, Inc. and its innovative point-of-care diagnostic tests for infectious diseases. Committed to improving healthcare with rapid testing solutions.",
        "keywords": [
            "Chembio",
            "Diagnostics",
            "Rapid Tests",
            "Infectious Diseases",
            "COVID-19",
            "HIV Testing",
            "Syphilis Testing"
        ]
    },
    "faq": [
        {
            "question": "What does Chembio specialize in?",
            "answer": "Chembio specializes in rapid diagnostic tests for infectious diseases."
        },
        {
            "question": "Who is the CEO of Chembio?",
            "answer": "Richard Eberly is the CEO of Chembio Diagnostics, Inc."
        },
        {
            "question": "Where is Chembio headquartered?",
            "answer": "Chembio is headquartered in Hauppauge, New York, USA."
        },
        {
            "question": "What types of tests does Chembio offer?",
            "answer": "Chembio offers tests for HIV, syphilis, and COVID-19 among others."
        },
        {
            "question": "When was Chembio founded?",
            "answer": "Chembio was founded in 1985."
        }
    ],
    "competitors": [
        "ABT",
        "BDX",
        "RMD"
    ],
    "related_stocks": [
        "PFE",
        "MRNA",
        "JNJ",
        "GILD"
    ]
}